ES2653265T3 - Morfinanos sustituidos y el uso de éstos - Google Patents

Morfinanos sustituidos y el uso de éstos Download PDF

Info

Publication number
ES2653265T3
ES2653265T3 ES13823996T ES13823996T ES2653265T3 ES 2653265 T3 ES2653265 T3 ES 2653265T3 ES 13823996 T ES13823996 T ES 13823996T ES 13823996 T ES13823996 T ES 13823996T ES 2653265 T3 ES2653265 T3 ES 2653265T3
Authority
ES
Spain
Prior art keywords
cycloalkyl
cycloalkenyl
heterocycle
alkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13823996T
Other languages
English (en)
Inventor
Andrew KASSICK
Laykea Tafesse
Jeffrey Lockman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma LP filed Critical Purdue Pharma LP
Application granted granted Critical
Publication of ES2653265T3 publication Critical patent/ES2653265T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto que tiene la Fórmula I-A: **(Ver fórmula)** o una sal o solvato farmacéuticamente aceptable de éste, en el que: R1 es hidrógeno, OH, halo, ciano, carboxi, o aminocarbonilo; o alquilo, alquenilo, alquinilo, alcoxi, alqueniloxi, o alquiniloxi, cualquiera de los cuales está sustituido opcionalmente con 1, 2, ó 3 sustituyentes, cada uno seleccionado independientemente del grupo que consiste en hidroxi, halo, haloalquilo, amino, alquilamino, dialquilamino, carboxi, alcoxi, alcoxicarbonilo, arilo, heteroarilo, heterociclo, cicloalquilo, y cicloalquenilo, en el que el arilo, heteroarilo, heterociclo, cicloalquilo, y cicloalquenilo están sustituidos opcionalmente con 1, 2, ó 3 grupos R11a seleccionados independientemente; R2 es: (a) hidrógeno o carboxamido; o (b) alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, heterociclo, arilo, heteroarilo, (cicloalquil)alquilo, (cicloalquenil)alquilo, (heterociclo)alquilo, arilalquilo, heteroarilalquilo, alquilcarbonilo, alcoxicarbonilo, (arilalcoxi)carbonilo, o (heteroarilalcoxi)carbonilo, cualquiera de los cuales está sustituido opcionalmente con 1, 2, ó 3 sustituyentes, cada uno seleccionado independientemente del grupo que consiste en hidroxi, alquilo, halo, haloalquilo, amino, alquilamino, dialquilamino, carboxi, alcoxi, alcoxicarbonilo, arilo, heteroarilo, heterociclo, cicloalquilo, y cicloalquenilo, en el que el arilo, heteroarilo, heterociclo, cicloalquilo, y cicloalquenilo están sustituidos opcionalmente con 1, 2, ó 3 grupos R11a seleccionados independientemente; R3 es hidrógeno, OH, o halo; o alcoxi, alquilamino, o dialquilamino, cualquiera de los cuales está sustituido opcionalmente con 1, 2, ó 3 sustituyentes, cada uno seleccionado independientemente del grupo que consiste en hidroxilo, halo, haloalquilo, amino, alquilamino, dialquilamino, carboxi, alcoxi, alcoxicarbonilo, arilo, heteroarilo, heterociclo, cicloalquilo, y cicloalquenilo, en el que el arilo, heteroarilo, heterociclo, cicloalquilo, y cicloalquenilo están sustituidos opcionalmente con 1, 2, ó 3 grupos R11a seleccionados independientemente; R4a1 se selecciona del grupo que consiste en alquilo C3-C6, arilalquilo, (cicloalquil)alquilo, alcoxi C3-C6, aralquiloxi, -N(H)COR4c, -CH2C(>=O)NR4dR4e, -N(H)SO2R4f, **(Ver fórmula)** ...
ES13823996T 2012-12-28 2013-12-23 Morfinanos sustituidos y el uso de éstos Active ES2653265T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746878P 2012-12-28 2012-12-28
PCT/IB2013/002883 WO2014102593A1 (en) 2012-12-28 2013-12-23 Substituted morphinans and the use thereof

Publications (1)

Publication Number Publication Date
ES2653265T3 true ES2653265T3 (es) 2018-02-06

Family

ID=50000021

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13823996T Active ES2653265T3 (es) 2012-12-28 2013-12-23 Morfinanos sustituidos y el uso de éstos

Country Status (9)

Country Link
US (2) US8946255B2 (es)
EP (1) EP2941431B1 (es)
JP (1) JP6159417B2 (es)
AR (1) AR094646A1 (es)
CA (1) CA2896202A1 (es)
ES (1) ES2653265T3 (es)
IL (1) IL239643A0 (es)
TW (1) TW201441199A (es)
WO (1) WO2014102593A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013003354A (es) 2010-09-21 2013-06-24 Purdue Pharma Lp Analogos de buprenorfina.
EP3333156A3 (en) 2012-11-09 2018-09-26 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US9175000B2 (en) 2012-12-07 2015-11-03 Purdue Pharma L.P. Buprenorphine analogs
WO2014091297A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Spirocyclic morphinans and their use
TWI513697B (zh) 2012-12-14 2015-12-21 Purdue Pharma Lp 吡啶酮並嗎啡喃類似物及其對類鴉片受體之生物活性
US9056836B2 (en) 2013-01-31 2015-06-16 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
EP3087073B1 (en) 2013-12-26 2018-07-04 Purdue Pharma LP 10-substituted morphinan hydantoins
AU2014370062A1 (en) 2013-12-26 2016-08-11 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
EP3087079B1 (en) 2013-12-26 2019-04-03 Purdue Pharma LP Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
US10550088B2 (en) 2013-12-27 2020-02-04 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
JP2017521373A (ja) 2014-05-27 2017-08-03 パーデュー、ファーマ、リミテッド、パートナーシップ スピロ環モルフィナン及びその使用
EP3154972A4 (en) 2014-06-13 2017-11-22 Purdue Pharma L.P. Azamophinan derivatives and use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
MD3344248T2 (ro) * 2015-09-02 2022-10-31 Trevena Inc Aza-heterociclic cu 6 elemente conținând compuși de modulare a receptorului delta-opioid, metode de utilizare și fabricare a acestora
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
GB201719667D0 (en) * 2017-11-27 2018-01-10 Johnson Matthey Plc Process
WO2021015109A1 (ja) 2019-07-19 2021-01-28 日本ケミファ株式会社 フェノール誘導体の製造方法
AR125188A1 (es) 2021-03-22 2023-06-21 Neurocrine Biosciences Inc Inhibidores del vmat2 y métodos de uso

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2178010A (en) 1937-02-03 1939-10-31 Small Lyndon Frederick Nuclear substituted derivatives of the morphine series and methods for their preparation
GB1031364A (en) 1962-04-09 1966-06-02 Shionogi & Co Improvements in or relating to 6-hydroxymorphinan derivatives and their production
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
CA1093070A (en) 1978-02-10 1981-01-06 Michael P. Kotick 8.beta.-ALKYL-SUBSTITUTED MORPHINAN-6-ONE COMPOUNDS
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
CA1135692A (en) * 1979-05-21 1982-11-16 Michael P. Kotick 7-methyl and 7-methyl-8-lower alkyl b/c cis or trans morphinan-6-one compounds
US4242514A (en) 1979-10-17 1980-12-30 Miles Laboratories, Inc. Method for the introduction of a methyl group into the 7 position of the morphinan nucleus
US4362733A (en) 1981-06-29 1982-12-07 Miles Laboratories, Inc. N-Cyclopropylmethyl-14-ethoxymorphinan-6-one compounds exhibiting mixed analgesic/narcotic antagonist activity and precursors therefore
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4423221A (en) * 1982-06-10 1983-12-27 Sisa Pharmaceutical Laboratories, Inc. 7-Carboethoxy-morphinan-6-one compounds
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4912114A (en) 1988-03-18 1990-03-27 Sandoz Ltd. Morphinan derivatives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
KR19990077125A (ko) 1996-01-10 1999-10-25 파올로 비지, 엔리꼬 카쭐라니 헤테로고리-축합 모르핀 유도체 (ⅱ)
US6067749A (en) 1996-07-11 2000-05-30 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine and oripavine
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
EP0829481A1 (en) 1996-09-16 1998-03-18 Pfizer Inc. Morphinan hydroxamic acid compounds
EP1210084A4 (en) 1999-08-13 2002-11-13 Southern Res Inst PYRIDOMORPHINANS, THIENOMORPHINANS AND THEIR USE
NZ528241A (en) * 2001-03-02 2004-08-27 Euro Celtique S N-but-3-enyl norbuprenorphine and methods of use
DE10229842A1 (de) 2002-07-03 2004-02-05 Helmut Prof. Dr. Schmidhammer Morphinanderivate und deren quartäre Ammoniumsalze substituiert in Position 14, Herstellungsverfahren und Verwendung
JP2006502190A (ja) 2002-09-18 2006-01-19 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ デルタ−オピオイド受容体に選択的なオピエート類似物
KR101255074B1 (ko) 2003-10-01 2013-04-16 아돌로 코포레이션 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법
GB0421687D0 (en) 2004-09-30 2004-11-03 Johnson Matthey Plc Preparation of opiate analgesics
HRP20090594T1 (hr) 2005-02-16 2009-12-31 Micromet Ag Upotreba aktiviranih polimera za odvajanje proteina i polipeptidnih multimera
KR20080081057A (ko) 2005-12-21 2008-09-05 도레이 가부시끼가이샤 진해제
EP2099456A2 (en) 2006-11-22 2009-09-16 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
CN101210016B (zh) 2006-12-29 2011-07-20 中国科学院上海药物研究所 一类杂环并吗啡喃类化合物、制备方法及用途
JP2008179554A (ja) 2007-01-24 2008-08-07 Toray Ind Inc ピロール縮合モルヒナン誘導体およびその医薬用途
MX2009012281A (es) 2007-05-16 2009-12-01 Rensselaer Polytech Inst Opioides heterociclicos de anillo fusionado.
ES2748274T3 (es) 2007-10-05 2020-03-16 Toray Industries Remedio para aliviar los problemas de la piel que comprende un derivado de morfinano o una sal de adición de ácido farmacológicamente aceptable del mismo como el principio activo
WO2009059048A2 (en) 2007-10-30 2009-05-07 The Regents Of The University Of Colorado (+)-opioids and methods of use
WO2009067275A1 (en) 2007-11-21 2009-05-28 Progenics Pharmaceuticals, Inc N-oxides of 4,5-epoxy-morphinanium analogs
AU2008331235C1 (en) 2007-11-30 2013-01-17 Purdue Pharma L.P. Benzomorphan Compounds
NZ586203A (en) 2007-12-17 2012-10-26 Mallinckrodt Llc Process and compounds for the production of (+) opiates
AU2008338906B2 (en) 2007-12-17 2013-06-27 SpecGx LLC Processes for the production of (+)-'nal' morphinan compounds
CA2731939C (en) * 2008-07-30 2017-05-23 Purdue Pharma L.P. Buprenorphine analogs
US20110015219A1 (en) * 2009-07-16 2011-01-20 Mallinckrodt Inc. (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof
JP5728084B2 (ja) 2010-07-08 2015-06-03 アルカーメス ファーマ アイルランド リミテッド 置換モルフィナンの合成のための方法
BR112013011593B1 (pt) 2010-11-12 2022-02-22 Shionogi & Co., Ltd Sal de ácido p-toluenossulfônico
US8987293B2 (en) * 2010-12-23 2015-03-24 Phoenix Pharmalabs, Inc. Morphinans useful as analgesics
ES2629185T3 (es) 2011-08-26 2017-08-07 Deutsche Diabetes-Forschungsgesellschaft e. V. Derivados de morfinano para el tratamiento de la diabetes y trastornos relacionados
JP6061857B2 (ja) 2011-09-09 2017-01-18 学校法人北里研究所 モルヒナン誘導体
US8937084B2 (en) 2012-12-14 2015-01-20 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof

Also Published As

Publication number Publication date
IL239643A0 (en) 2015-08-31
US8946255B2 (en) 2015-02-03
JP6159417B2 (ja) 2017-07-05
AR094646A1 (es) 2015-08-19
WO2014102593A1 (en) 2014-07-03
TW201441199A (zh) 2014-11-01
US20150175571A1 (en) 2015-06-25
CA2896202A1 (en) 2014-07-03
JP2016509588A (ja) 2016-03-31
US20140187573A1 (en) 2014-07-03
US9388162B2 (en) 2016-07-12
EP2941431A1 (en) 2015-11-11
EP2941431B1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
ES2653265T3 (es) Morfinanos sustituidos y el uso de éstos
CR20170066A (es) Compuestos aminopirimidinilo como inhibidires de jak
PH12016501007A1 (en) Substituted benzamides and methods of use thereof
MX2019010100A (es) Compuesto de quinolona.
AR094647A1 (es) Análogos de 7,8-morfinano cíclico
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
PH12014500434A1 (en) New dihydroquinoline-2-one derivatives
MX2015010775A (es) Benzoxazoles sustituidos y metodos para usarlos.
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
MX2015011436A (es) Triazolopiridinas sustituidas y metodos para usarlas.
MX2015007883A (es) Compuestos para protección de células.
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين
JO3509B1 (ar) معدلات p2x7
MY172860A (en) Dimethyl-benzoic acid compounds
MX2015017156A (es) Inhibidores de bace.
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.
PH12015500009A1 (en) Phenoxyethyl piperidine compounds
ES2721658T3 (es) 3,4-dihidro-1h-[1,8]naftiridinonas sustituidas con ciclopenta[c]pirrol antibacterianas
MY161134A (en) Piperazine compound having a pgds inhibitory effect
ES2553030T3 (es) Compuestos plaguicidas
CR20190236A (es) Compuestos terapéuticos y métodos para utilizarlos
CO2018010787A2 (es) Compuesto de griseofulvina
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.